Journal of Dermatological Treatment
Volume 34, 2023 - Issue 1
Research Article
Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial
Kenji Kabashimaa Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, JapanCorrespondence[email protected]
https://orcid.org/0000-0002-0773-0554View further author information
https://orcid.org/0000-0002-0773-0554View further author information, Takayo Matsumurab Department of Clinical Development, Maruho Co., Ltd., Kyoto, Japanhttps://orcid.org/0000-0002-0986-8469View further author information
https://orcid.org/0000-0002-0986-8469View further author information, , Makoto Kawashimad Tokyo Women’s Medical University, Tokyo, Japanhttps://orcid.org/0000-0001-6877-9979View further author information
https://orcid.org/0000-0001-6877-9979View further author information & for the Nemolizumab-JP01 Study Group